• Apabetalone decreases endothelial chemokine secretion and endothelium-monocyte adhesion in a BBB model.
• This may reduce immune cell transmigration into the brain during neurovascular inflammation and neurodegeneration.
• Apabetalone may improve BBB function during aging due to alkaline phosphatase reduction (Haarhaus 2019 , Curr Opin Nephol Hyperten).
• These effects may contribute to the favourable effect of apabetalone on cognition in patients from the phase 3 cardiovascular outcomes trial (BETonMACE).

Some of this seems new.  Especially conclusion claim #3.